PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32738844-10 2020 SBP and DBP goals were achieved by 40.4% and 50.3% of patients on olmesartan monotherapy and by 36.1% and 46.2% of patients on olmesartan+1AHD. olmesartan 66-76 D-box binding PAR bZIP transcription factor Homo sapiens 8-11 34440064-8 2021 We found some little difference in the behaviour of the three treatments on some variables: olmesartan was the most effective in reducing fibrinogen, DBP, CRP, and AIx (-13.1%, -19.3%, -21.4%, and -56.8%, respectively). olmesartan 92-102 D-box binding PAR bZIP transcription factor Homo sapiens 150-153 32738844-12 2020 SBP and DBP goals were achieved by 38.5% and 49.4% of patients on olmesartan monotherapy and by 31.7% and 42.9% of patients on olmesartan+1AHD. olmesartan 66-76 D-box binding PAR bZIP transcription factor Homo sapiens 8-11 17323586-2 2006 In pooled analyses of seven randomized, double-blind trials, 8 weeks" treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). olmesartan 85-95 D-box binding PAR bZIP transcription factor Homo sapiens 287-290 26867060-6 2016 RESULTS: The olmesartan/amlodipine combination reached noninferiority criteria in reduction of office DBP after 24 weeks of treatment and after the missed dose, compared with the perindopril/amlodipine combination (-11.7 and -10.5 mmHg, respectively). olmesartan 13-23 D-box binding PAR bZIP transcription factor Homo sapiens 102-105 24942766-5 2014 During Period II, each olmesartan/amlodipine combination reduced 24-h systolic and diastolic BP (SBP/DBP), as well as morning and early morning SBP/DBP, significantly more than amlodipine 5 mg (P<0.001 for all). olmesartan 23-33 D-box binding PAR bZIP transcription factor Homo sapiens 101-104 24942766-5 2014 During Period II, each olmesartan/amlodipine combination reduced 24-h systolic and diastolic BP (SBP/DBP), as well as morning and early morning SBP/DBP, significantly more than amlodipine 5 mg (P<0.001 for all). olmesartan 23-33 D-box binding PAR bZIP transcription factor Homo sapiens 148-151 22573127-4 2012 RESULTS: In 715 patients with valid baseline and end-of-treatment recordings baseline-adjusted 24-h SBP and DBP reductions were greater with olmesartan medoxomil (n = 356) than with ramipril (n = 359) [between-treatment differences and 95% confidence interval (CI), SBP: 2.2 (3.8, 0.6), P = 0.006; DBP: 1.3 (2.2, 0.3), P = 0.009]. olmesartan 141-151 D-box binding PAR bZIP transcription factor Homo sapiens 108-111 24942766-6 2014 TPRs were higher in each olmesartan/amlodipine group than with amlodipine 5 mg, and SI values showed dose-related increases; olmesartan/amlodipine 40/5 mg produced a significantly higher SI for SBP and DBP (1.55 and 1.33, respectively) than amlodipine 5 mg (0.96 and 0.77, respectively, P<0.0001 for each). olmesartan 125-135 D-box binding PAR bZIP transcription factor Homo sapiens 202-205 19655819-1 2009 BACKGROUND: The combination of olmesartan medoxomil and hydrochlorothiazide (HCTZ) [olmesartan medoxomil/HCTZ] has previously been shown to produce significantly greater SBP/DBP reductions than monotherapy with either agent alone in a randomized, double-blind, factorial study in patients with stage 2 hypertension. olmesartan 31-41 D-box binding PAR bZIP transcription factor Homo sapiens 174-177 19655819-1 2009 BACKGROUND: The combination of olmesartan medoxomil and hydrochlorothiazide (HCTZ) [olmesartan medoxomil/HCTZ] has previously been shown to produce significantly greater SBP/DBP reductions than monotherapy with either agent alone in a randomized, double-blind, factorial study in patients with stage 2 hypertension. olmesartan 84-94 D-box binding PAR bZIP transcription factor Homo sapiens 174-177 19655819-9 2009 All combined SBP/DBP goals were achieved by a statistically significant proportion of patients (p < 0.05) in the olmesartan medoxomil/HCTZ 20/25, 40/12.5, and 40/25 treatment groups. olmesartan 116-126 D-box binding PAR bZIP transcription factor Homo sapiens 17-20 17391291-8 2007 BP-lowering efficacy defined as E(max) was superior with olmesartan, (DBP/SBP mmHg: -9.0/-12.4) when compared with candesartan (-6.7/-11.3), irbesartan (-6.5/-11.2) and valsartan (-6.3/-8.9). olmesartan 57-67 D-box binding PAR bZIP transcription factor Homo sapiens 70-73 17953475-12 2007 The LS mean change for reduction in DBP approached statistical significance with olmesartan medoxomil/HCTZ compared with the benazepril-based regimen (p=0.056) at week 12 (end of study). olmesartan 81-91 D-box binding PAR bZIP transcription factor Homo sapiens 36-39 17953475-13 2007 BP reductions showed statistically significant differences between treatment groups favoring olmesartan medoxomil/HCTZ in both SBP and DBP at week 8. olmesartan 93-103 D-box binding PAR bZIP transcription factor Homo sapiens 135-138 17217710-8 2006 (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. olmesartan 124-134 D-box binding PAR bZIP transcription factor Homo sapiens 49-52 17535053-6 2003 RESULTS: Mean decreases from baseline in daytime DBP by ABPM at weeks 1, 2 and 8 were 6.7, 8.4 and 9.3mm Hg, respectively, in the olmesartan medoxomil group compared with 5.3, 6.0 and 7.8mm Hg, respectively, in the candesartan cilexetil group. olmesartan 130-140 D-box binding PAR bZIP transcription factor Homo sapiens 49-52 17535053-8 2003 Significant differences in favour of olmesartan medoxomil were also observed for mean 24-hour DBP and for mean daytime and 24-hour SBP by ABPM. olmesartan 37-47 D-box binding PAR bZIP transcription factor Homo sapiens 94-97 17535053-11 2003 CONCLUSIONS: Olmesartan medoxomil reduced daytime and 24-hour DBP and SBP, assessed by ABPM, more effectively than candesartan cilexetil at the doses tested. olmesartan 13-23 D-box binding PAR bZIP transcription factor Homo sapiens 62-65 17532689-10 2005 However, both SBP and DBP were significantly lower in the olmesartan group than in the losartan group after treatment. olmesartan 58-68 D-box binding PAR bZIP transcription factor Homo sapiens 22-25 17532689-12 2005 After 4 weeks of treatment, the reduction in BP values was larger in the olmesartan group than in the losartan group (decreases in DBP of 12.1 +/- 8.4mm Hg vs 7.2 +/- 6.8mm Hg [p < 0.005] and in SBP of 15.1 +/- 13.0mm Hg vs 10.3 +/- 10.1mm Hg [p < 0.05] for the olmesartan and losartan groups, respectively). olmesartan 73-83 D-box binding PAR bZIP transcription factor Homo sapiens 131-134